Maxim Group Reiterates Buy on PainReform, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Naz Rahman has reiterated a Buy rating on PainReform (NASDAQ:PRFX) and maintained a $2 price target.
June 26, 2024 | 3:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maxim Group analyst Naz Rahman has reiterated a Buy rating on PainReform (NASDAQ:PRFX) and maintained a $2 price target.
The reiteration of a Buy rating and the maintenance of a $2 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100